Christopher A. Klebanoff
- Immunology top 0.1%
- Immunotherapy and Immune Responses 39
- Immune Cell Function and Interaction 29
- T-cell and B-cell Immunology 23
- Immune cells in cancer 4
- Oncology top 0.1%
- CAR-T cell therapy research 49
- Cancer Immunotherapy and Biomarkers 20
- Genetics top 1%
- Virus-based gene therapy research 7
- Cancer Research top 2%
- Molecular Biology top 2%
-
- Monoclonal and Polyclonal Antibodies Research 4
- Co-authors
- Nicholas P. RestifoLuca GattinoniDouglas C. PalmerSteven A. RosenbergPaul A. AntonyZhiya YuSteven E. FinkelsteinSmita S. Chandran
- Cited by
- ImmunologyOncologyGenetics
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
Christopher A. Klebanoff
73 papers receiving 11.6k citations
Hit Papers
Peers
Comparison fields: 5 of 128
- Immunology 7.9k
- Oncology 7.9k
- Genetics 1.7k
- Cancer Research 685
- Molecular Biology 3.0k
Countries citing papers authored by Christopher A. Klebanoff
This map shows the geographic impact of Christopher A. Klebanoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher A. Klebanoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher A. Klebanoff more than expected).
Fields of papers citing papers by Christopher A. Klebanoff
This network shows the impact of papers produced by Christopher A. Klebanoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher A. Klebanoff. The network helps show where Christopher A. Klebanoff may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Christopher A. Klebanoff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 4 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2020 | 24 | |
| 5 | 2020 | 26 | |
| 6 | 2018 | 204 | |
| 7 | 2018 | 9 | |
| 8 | 2017 | 279 | |
| 9 | Ionic immune suppression within the tumour microenvironment limits T cell effector functionbreakdown → | 2016 | 489 |
| 10 | 2016 | 199 | |
| 11 | 2015 | 139 | |
| 12 | 2011 | 225 | |
| 13 | 2010 | 217 | |
| 14 | 2008 | 358 | |
| 15 | 2006 | 101 | |
| 16 | 2006 | 6 | |
| 17 | Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cellsbreakdown → | 2005 | 812 |
| 18 | CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cellsbreakdown → | 2005 | 585 |
| 19 | 2004 | 481 | |
| 20 | 2004 | 97 |
About Christopher A. Klebanoff
Christopher A. Klebanoff is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 77 papers that have together received 11.7k indexed citations. Recurring topics across this work include CAR-T cell therapy research (49 papers), Immunotherapy and Immune Responses (39 papers), Immune Cell Function and Interaction (29 papers), T-cell and B-cell Immunology (23 papers), Cancer Immunotherapy and Biomarkers (20 papers), Virus-based gene therapy research (7 papers), Immune cells in cancer (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Immunology (7.9k citations), Oncology (7.9k citations) and Genetics (1.7k citations). Christopher A. Klebanoff has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Nicholas P. Restifo, Luca Gattinoni, Douglas C. Palmer, Steven A. Rosenberg, Paul A. Antony, Zhiya Yu, Steven E. Finkelstein, Smita S. Chandran, Madhusudhanan Sukumar and Paul J. Spiess. Their work appears in journals such as Nature, Science and Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.